Exciting Hematology Symposia in Conjunction with 2023 ASH Annual Meeting

DEC 8TH 7:00 AM PT
Morning Session (Breakfast Included)

• The Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  Discussion Includes:
   

  • NCCN guidelines review for first-line and second-line regimens
  • Key variables in deciding between regimens
  • Mastering the current regimen components
    • Including MOA, key efficacy and safety data, and other considerations with BTK inhibitors, BCL-2 inhibitors, and anti-CD20 mAbs
  • Effective management of CLL
  • MRD, CAR T-cell therapy, and noncovalent BTK inhibitors
  • ASH 2023 CLL abstract highlight

  Faculty:
   

  • Danielle Brander, MD
  • Deborah Stephens, DO
  • Brian Hill, MD, PhD

  Room Name:
   

  • Pacific Ballroom 21-22

DEC 8TH

11:00 AM PT
Morning Sessions (Lunch Included)

• An MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes

  Discussion Includes:
   

  • Quiz and discussion 1: Changes to the MCL Treatment Landscape
  • Current treatment algorithm
  • Role of BTKis
  • Unmet clinical needs
  • Quiz and discussion 2: Current/Emerging Roles of BTKis in Untreated MCL
  • Mechanisms, PK/PD, and efficacy of BTKis
  • BTKis in transplant-eligible patients
  • Improving on BR in first-line MCL without transplant
  • Quiz and discussion 3: Selecting and Sequencing BTKis in R/R MCL
  • Resistance and intolerance to covalent BTKis
  • Treatment options and sequencing after BR plus BTKi
  • Panel discussions: New Data on Current Clinical Challenges
  • Combining and sequencing of novel agents
  • Overcoming barriers to and challenges with BTKi therapy
  • Key abstracts at SOHO 2023 and ASH 2023
  • Closing Remarks, Audience Question and Answer Session
    

  Faculty:
   

  • Ann LaCasce, MD, MMSc
  • John P. Leonard, MD
  • Matthew Lunning, DO, FACP

  Room Name:
   

  • Pacific Ballroom 21-22

• A Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes

  Discussion Includes:
   

  • Partnering with Patients to Improve Outcomes and Quality of Life
  • Selecting Initial Treatment for Patients with Myelofibrosis
  • Recognizing Patterns of Suboptimal Response to First Line Myelofibrosis Treatment
  • Disease Progression or Intolerance to Initial Therapy
  • What's on the Horizon in Myelofibrosis Treatment

  Faculty:
   

  • Jean-Jacques Kiladjian, MD, PhD
  • Abdulraheem Yacoub, MD

  Room Name:
   

  • San Diego Ballroom AB

DEC 8TH

3:00 PM PT
Afternoon Sessions (Refreshments Included)

• AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches

  Discussion Includes:
   

  • Biology, clinical presentation, and diagnostic approach for AL amyloidosis
  • Overview of recent treatment guidelines
  • Current/evolving management algorithm for patients with newly diagnosed AL amyloidosis
  • Current/evolving algorithm for the management of AL amyloidosis at relapse
  • Clinical trial spotlight and review of key abstracts to be presented at ASH 2023

  Faculty:
   

  • Angela Dispenzieri, MD
  • Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM

  Room Name:
   

  • Pacific Ballroom 21-22

• Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

  Discussion Includes:
   

  • Welcome, Introduction, and Baseline Assessment
  • Pathophysiology and Classification of CAD
    • Diagnostic criteria and current challenges
  • Current Data in the Therapeutic Management of CAD
    • CAD mechanism of action
    • Historical management
    • Targeted therapies: complement pathway inhibition
  • Future Directions
    • Novel agents in development
    • Clinical trial spotlight: key abstracts from ASH
  • Final Thoughts and Audience Question and Answer Session

  Faculty:
   

  • Catherine M. Broome, MD
  • David Dingli, MD, PhD
  • Deva Sharma, MD, MS

  Room Name:
   

  • San Diego Ballroom AB

• An Expert Guide to What's New and What's Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

  Discussion Includes:
   

  • Welcome and Introduction
  • Overview of R/R FL and Unmet Needs
  • Patient Selection and Sequencing of New and Emerging Options For R/R FL
    • Bispecific Antibodies
    • Epigenetic Modifiers
    • PI3K Inhibitors
    • CAR T-Cell Therapy
  • Future Directions in R/R FL
  • Audience Question and Answer Session

  Faculty:
   

  • Peter Martin, MD
  • Sonali Smith, MD, FASCO
  • Julie Vose, MD

  Room Name:
   

  • Pacific Ballroom 18-19